Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT ID: NCT07787182
Registry status: Not yet recruiting
Study type: Interventional
Phase: Phase 1
Sponsor: Eli Lilly and Company
Conditions: Alzheimer Disease, Amyloid, Healthy Volunteers, Plaque, Amyloid

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Enrollment: 68 participants (Estimated).

What is being studied

Intervention: 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
Other: Florbetaben F 18
Intervention: florbetapir
Other: Florbetapir F18
Drug: LY4405094
Drug: Placebo

Who may be eligible

Ages: 18 Years to 85 Years
Sex: All
Healthy volunteers accepted: Yes

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study. Exclusion Criteria: * Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094. * Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

Study locations

16 study locations are listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: China, Japan, United States

California, United States: 3
Florida, United States: 8
Georgia, United States: 1
Michigan, United States: 1

Sample of listed locations

Xuanwu Hospital Capital Medical University — Beijing, 100053, China — Site recruitment status not specified in the registry data
The University of Tokyo Hospital — Bunkyō City, 113-8655, Japan — Site recruitment status not specified in the registry data
National Center for Geriatrics and Gerontology — Ōbu, 4748511, Japan — Site recruitment status not specified in the registry data
CenExel ACT — Anaheim, California, 92801, United States — Site recruitment status not specified in the registry data
Irvine Clinical Research — Irvine, California, 92614, United States — Site recruitment status not specified in the registry data
Collaborative Neuroscience Network - CNS — Los Alamitos, California, 90720, United States — Site recruitment status not specified in the registry data
Fortrea Clinical Research Unit — Daytona Beach, Florida, 32117, United States — Site recruitment status not specified in the registry data
K2 Medical Research - The Villages — Lady Lake, Florida, 32159, United States — Site recruitment status not specified in the registry data
K2 Medical Research — Maitland, Florida, 32751, United States — Site recruitment status not specified in the registry data
Charter Research — Orlando, Florida, 32803, United States — Site recruitment status not specified in the registry data
Progressive Medical Research — Port Orange, Florida, 32127, United States — Site recruitment status not specified in the registry data
Alzheimer's Research and Treatment Center — Stuart, Florida, 34996, United States — Site recruitment status not specified in the registry data
K2 Medical Research - Tampa — Tampa, Florida, 33634, United States — Site recruitment status not specified in the registry data
Charter Research — The Villages, Florida, 32162-2698, United States — Site recruitment status not specified in the registry data
Accel Research Sites - NeuroStudies Clinical Research Unit — Decatur, Georgia, 30030, United States — Site recruitment status not specified in the registry data
QUEST Research Institute — Farmington Hills, Michigan, 48334, United States — Site recruitment status not specified in the registry data

Study details

Start date: September 1, 2026
Primary completion date: January 1, 2028
Completion date: January 1, 2028
First posted: August 26, 2026

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07787182
Registry last updated: September 22, 2026
QualifiedStudies registry data refreshed: September 28, 2026
QualifiedStudies record fetched: September 28, 2026

View NCT07787182 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Alzheimers Disease studies | Clinical trial FAQ